Lilly Gets Back Into the Vaccine Business With New Deals

Eli Lilly is acquiring three clinical-stage vaccine developers for as much as $3.8 billion, a strategic push to build a larger infectious-disease franchise. The deal reflects Lilly’s use of cash generated by its obesity drugs to diversify into other therapeutic areas. The announcement is positive for Lilly’s long-term pipeline strategy and could support sentiment toward the company and the broader biotech M&A space.

Analysis

Eli Lilly is acquiring three clinical-stage vaccine developers for as much as $3.8 billion, a strategic push to build a larger infectious-disease franchise. The deal reflects Lilly’s use of cash generated by its obesity drugs to diversify into other therapeutic areas. The announcement is positive for Lilly’s long-term pipeline strategy and could support sentiment toward the company and the broader biotech M&A space.